MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ko, Jihoon | - |
dc.contributor.author | Jung, Jaeyun | - |
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Hong, Jung Yong | - |
dc.contributor.author | Park, Sehhoon | - |
dc.contributor.author | Park, Joon Oh | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Ahn, Soomin | - |
dc.contributor.author | Kim, Kyoung-Mee | - |
dc.contributor.author | Kang, Won Ki | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.date.accessioned | 2023-03-27T06:40:48Z | - |
dc.date.available | 2023-03-27T06:40:48Z | - |
dc.date.created | 2023-03-27 | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 1219-4956 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87282 | - |
dc.description.abstract | Background: To aid in oncology drug development, we investigated MET proto-oncogene receptor tyrosine kinase gene aberrations in 2,239 oncology patients who underwent next-generation sequencing (NGS) in clinical practice.Materials and methods: From November 2019 to January 2021, 2,239 patientswith advanced solid tumors who visited oncology clinics underwent NGS. The NGS panel included > 500 comprehensive NGS tests using archival tissue specimens. Programmed death-ligand 1(PD-L1) 22C3 assay results and clinical records regarding initial chemotherapy were available for 1,137 (50.8%) and 1,761 (78.7%) patients, respectively for overall survival (OS) analysis.Results: The 2,239 patients represented 37 types of cancer. The NGS panel included > 500 genes, microsatellite instability status, tumor mutational burden, and fusions. The most common cancer types were colorectal (N = 702), gastric (N = 481), and sarcoma (N = 180). MET aberrations were detected in 212 patients. All MET-amplified tumors had microsatellite stable status, and 8 had a high tumor mutational burden. Of 46 patients with MET-amplified cancers, 8 had MET-positive protein expression by immunohistochemistry (2+ and 3+). MET fusion was detected in 10 patients. Partner genes of MET fusion included ST7, TFEC, LRRD1, CFTR, CAV1, PCM1, HLA-DRB1, and CAPZA2. In survival analysis, patients with amplification of MET gene fusion had shorter OS and progression-free survival (PFS) than those without. Thus, MET aberration was determined to be a factor of response to chemotherapy.Conclusion: Approximately 2.1% and 0.4% of patients with advanced solid tumors demonstrated MET gene amplification and fusion, respectively, and displayed a worse response to chemotherapy and significantly shorter OS and PFS than those without MET gene amplification or fusion. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.relation.isPartOf | PATHOLOGY & ONCOLOGY RESEARCH | - |
dc.title | MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000894427400001 | - |
dc.identifier.doi | 10.3389/pore.2022.1610697 | - |
dc.identifier.bibliographicCitation | PATHOLOGY & ONCOLOGY RESEARCH, v.28 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85143314934 | - |
dc.citation.title | PATHOLOGY & ONCOLOGY RESEARCH | - |
dc.citation.volume | 28 | - |
dc.contributor.affiliatedAuthor | Ko, Jihoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | next-generation sequencing | - |
dc.subject.keywordAuthor | oncogene | - |
dc.subject.keywordAuthor | overall survival analysis | - |
dc.subject.keywordAuthor | MET | - |
dc.subject.keywordAuthor | MET alterations | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordPlus | GASTRIC-CANCER | - |
dc.subject.keywordPlus | C-MET | - |
dc.subject.keywordPlus | AMPLIFICATION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | ONCOGENE | - |
dc.subject.keywordPlus | IMPACT | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.